Literature DB >> 3522558

Phenelzine for chronic depression: a study of continuation treatment.

W Harrison, J Rabkin, J W Stewart, P J McGrath, E Tricamo, F Quitkin.   

Abstract

Several controlled studies have demonstrated the efficacy of continuation therapy with tricyclic antidepressants, but little is known about continuation therapy with the monoamine oxidase inhibitors. Moreover, the usefulness of continuation antidepressant therapy in patients with chronic depressive disorders has not been evaluated. This pilot study reports initial results of a double-blind continuation trial of phenelzine or placebo following an initial antidepressant response to phenelzine in 12 patients who met DSM-III criteria for dysthymic disorder. All 7 patients randomized to placebo relapsed, whereas only 1 of the 5 patients who continued to receive phenelzine relapsed. These results suggest that continuation therapy with phenelzine may be useful in maintaining clinical response after acute treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3522558

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  10 in total

Review 1.  Continuation and maintenance therapy with antidepressive agents. An overview of research.

Authors:  A J Loonen; G J Zwanikken
Journal:  Pharm Weekbl Sci       Date:  1990-08-24

2.  Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults.

Authors:  Katja Machmutow; Ramona Meister; Alessa Jansen; Levente Kriston; Birgit Watzke; Martin Christian Härter; Sarah Liebherz
Journal:  Cochrane Database Syst Rev       Date:  2019-05-20

3.  Current Perspectives on the Diagnosis and Treatment of Double Depression.

Authors:  D J Hellerstein; S A Little
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

Review 4.  Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors.

Authors:  S H Kennedy
Journal:  J Psychiatry Neurosci       Date:  1997-03       Impact factor: 6.186

Review 5.  Benefits and risks of pharmacotherapy for dysthymia: a systematic appraisal of the evidence.

Authors:  Maurício S De Lima; Matthew Hotopf
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

6.  Depression With Atypical Features: Diagnostic Validity, Prevalence, and Treatment.

Authors:  Frederic M. Quitkin
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2002-06

7.  Influence of mirtazapine on the sexual behavior of male rats.

Authors:  Augusta Benelli; Claudio Frigeri; Alfio Bertolini; Susanna Genedani
Journal:  Psychopharmacology (Berl)       Date:  2003-11-13       Impact factor: 4.530

8.  Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults.

Authors:  Ellen Van Leeuwen; Mieke L van Driel; Mark A Horowitz; Tony Kendrick; Maria Donald; An Im De Sutter; Lindsay Robertson; Thierry Christiaens
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

9.  Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression.

Authors:  Paul W Andrews; Susan G Kornstein; Lisa J Halberstadt; Charles O Gardner; Michael C Neale
Journal:  Front Psychol       Date:  2011-07-07

Review 10.  Prevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled Trials.

Authors:  Kang Sim; Wai Keat Lau; Jordan Sim; Min Yi Sum; Ross J Baldessarini
Journal:  Int J Neuropsychopharmacol       Date:  2015-07-07       Impact factor: 5.176

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.